2006
The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M. The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal Of The American College Of Cardiology 2006, 47: 726-733. PMID: 16487836, DOI: 10.1016/j.jacc.2005.09.055.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina PectorisAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAtherosclerosisCaptoprilCardiovascular DiseasesDisease-Free SurvivalDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMyocardial InfarctionRandomized Controlled Trials as TopicRecurrenceStrokeTetrazolesValineValsartanConceptsAngiotensin receptor blockersAcute Myocardial Infarction trialMyocardial Infarction trialAtherosclerotic eventsMyocardial infarctionACE inhibitorsValsartan groupReceptor blockersEnzyme inhibitorsNon-fatal myocardial infarctionAngiotensin-converting enzyme inhibitorAnti-infarction effectSecondary preventive treatmentEffect of valsartanRenin-angiotensin systemBlood pressure differenceEffects of captoprilAcute myocardial infarctionCaptopril groupCombination groupPreventive treatmentLower riskEvidence gapsCaptoprilValsartan
2003
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal Of Medicine 2003, 349: 1893-1906. PMID: 14610160, DOI: 10.1056/nejmoa032292.Peer-Reviewed Original ResearchConceptsCaptopril groupValsartan groupMyocardial infarctionCardiovascular eventsAdverse eventsHeart failureMost drug-related adverse eventsDrug-related adverse eventsLeft ventricular systolic dysfunctionAngiotensin receptor blocker valsartanAngiotensin converting enzyme (ACE) inhibitorsEnd pointMyocardial Infarction ComplicatedNonfatal cardiovascular eventsDouble-blind trialPrimary end pointVentricular systolic dysfunctionComposite end pointLeft ventricular dysfunctionPopulation of patientsACE inhibitor captoprilAcute myocardial infarctionAdditional therapyCardiovascular morbidityRenal dysfunction